Results 21 to 30 of about 6,789 (241)

Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats [PDF]

Pharmaceuticals, 2022
We have previously demonstrated that the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) protects the liver via downregulation of hepatic matrix metalloproteinases (MMPs) after ischemia/reperfusion (I/R), which can lead to multiorgan ...
Giuseppina Palladini, Marta Cagna, Laura Giuseppina Di Pasqua, Luciano Adorini, Anna Cleta Croce, Stefano Perlini, Andrea Ferrigno, Clarissa Berardo, Mariapia Vairetti   +8 more
doaj   +2 more sources

Real-world experience with obeticholic acid in patients with primary biliary cholangitis [PDF]

JHEP Reports, 2021
Background & aims: Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid.
Daphne D’Amato, Antonio De Vincentis, Federica Malinverno, Mauro Viganò, Domenico Alvaro, Maurizio Pompili, Antonino Picciotto, Valeria Pace Palitti, Maurizio Russello, Silvia Storato, Marie Graciella Pigozzi, Vincenza Calvaruso, Elisabetta De Gasperi, Ana Lleo, Antonino Castellaneta, Adriano Pellicelli, Nora Cazzagon, Annarosa Floreani, Luigi Muratori, Stefano Fagiuoli, Grazia Anna Niro, Valentina Feletti, Raffaele Cozzolongo, Natalia Terreni, Marco Marzioni, Rinaldo Pellicano, Pietro Pozzoni, Leonardo Baiocchi, Luchino Chessa, Floriano Rosina, Gaetano Bertino, Maria Vinci, Anna Morgando, Ester Vanni, Gaetano Scifo, Rodolfo Sacco, Maria D’Antò, Valentina Bellia, Roberto Boldizzoni, Silvia Casella, Barbara Omazzi, Guido Poggi, Laura Cristoferi, Alessio Gerussi, Vincenzo Ronca, Rosanna Venere, Francesca Ponziani, Maria Cannavò, Alessandro Mussetto, Rosanna Fontana, Francesco Losito, Evelise Frazzetto, Marco Distefano, Francesca Colapietro, Sara Labanca, Giulia Marconi, Giuseppe Grassi, Giovanni Galati, Sarah Elizabeth O’Donnell, Clara Mancuso, Giacomo Mulinacci, Andrea Palermo, Ernesto Claar, Antonio Izzi, Antonio Picardi, Pietro Invernizzi, Marco Carbone, Umberto Vespasiani-Gentilucci   +67 more
doaj   +2 more sources

Hepatic‐Accumulated Obeticholic Acid and Atorvastatin Self‐Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic‐Associated Fatty Liver Disease [PDF]

Advanced Science
Exploration of medicines for efficient and safe management of metabolic‐associated fatty liver disease (MAFLD) remains a challenge. Obeticholic acid (OCA), a selective farnesoid X receptor agonist, has been reported to ameliorate injury and inflammation ...
Huanfen Lu, Zhenglan Ban, Kai Xiao, Madi Sun, Yongbo Liu, Fangman Chen, Tongfei Shi, Li Chen, Dan Shao, Ming Zhang, Wei Li   +10 more
doaj   +2 more sources

Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. [PDF]

Clin Liver Dis (Hoboken), 2021
Ratziu V.
europepmc   +4 more sources

Obeticholic acid for PBC [PDF]

Nature Reviews Gastroenterology & Hepatology, 2016
Hugh Thomas
openaire   +2 more sources

Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders. [PDF]

Pharmaceuticals (Basel)
Fiorucci S, Urbani G, Distrutti E, Biagioli M.   +3 more
europepmc   +3 more sources

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice. [PDF]

Front Pharmacol, 2022
Li S, Zhuge A, Wang K, Xia J, Wang Q, Han S, Shen J, Li L.   +7 more
europepmc   +3 more sources

Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. [PDF]

PLoS One
Adorini L, Rigbolt K, Feigh M, Roth J, Erickson M.   +4 more
europepmc   +2 more sources

Obeticholic Acid [PDF]

Journal of Pharmacy Technology, 2017
Objective: To review the pharmacology, efficacy, and safety of obeticholic acid (OCA) and determine its clinical role relative to other agents in the treatment of patients with primary biliary cholangitis (PBC). Data Sources: A PubMed search (1946 to November 2016) was conducted using the terms INT-747, obeticholic acid, OCA, farnesoid X receptor ...
Susan M. Smith, Angela H. Pegram
openaire   +1 more source

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma [PDF]

, 2019
Cholangiocarcinoma (CCA) is an aggressive cancer with high resistance to chemotherapeutics. CCA is enriched in cancer stem cells, which correlate with aggressiveness and prognosis.
Adorini, L., Alvaro, D., Berloco, P. B., Bragazzi, M., Cardinale, V., Carpino, G., Costantini, D., De Rose, A. M., Di Matteo, S., Gaudio, E., Giorgi, A., Giuliante, F., Giulitti, F., Grazi, G., Manzi, E., Melandro, F., Napoletano, C., Nevi, L., Overi, D., Safarikia, S.   +19 more
core   +3 more sources